A pilot phase II trial of all-trans retinoic acid (Vesanoid) and paclitaxel (Taxol) in patients with recurrent or metastatic breast cancer

Investigational New Drugs

Volumn 29, Issue 6, 2011, Pages 1482-1487

  Bryan, Margarette ^a   Pulte, E Dianne ^a   Toomey, Kathleen C ^b   Pliner, Lillian ^a   Pavlick, Anna C ^c   Saunders, Tracie ^a   Wieder, Robert ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b Somerset Medical Center   (United States)

^c NEW YORK UNIVERSITY   (United States)

Author keywords

All trans retinoic acid; Metastatic breast cancer; Potentiation; Taxol

Indexed keywords

PACLITAXEL; RETINOIC ACID; ANTINEOPLASTIC AGENT;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ATAXIA; BONE METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONSTIPATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HUMAN; LEUKOPENIA; LUNG EMBOLISM; METASTASIS; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; REPEATED DRUG DOSE; SEIZURE; SUPRAVENTRICULAR TACHYCARDIA; TREATMENT DURATION; VISCERAL METASTASIS; VOMITING; AFRICAN AMERICAN; BREAST TUMOR; CLINICAL TRIAL; DISEASE COURSE; HISPANIC; MIDDLE AGED; PATHOLOGY; PILOT STUDY; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR RECURRENCE;

AFRICAN AMERICANS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; HISPANIC AMERICANS; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; PILOT PROJECTS; SURVIVAL RATE; TREATMENT OUTCOME; TRETINOIN;

EID: 84856050828     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9478-3     Document Type: Article

References (20)

1. O'Shaughnessy J (2005) Extending survival with chemotherapy in metastatic breast cancer. Oncologist 10(Suppl 3):20-29 (Pubitemid 43152727)
2. Nabholtz JM, Gligorov J (2005) The role of taxanes in the treatment of breast cancer. Expert Opin Pharmacother 6:1073-1094 (Pubitemid 40959472)
3. Ghersi D, Wilcken N, Simes J, Donoghue E (2005) Taxane containing regimens for metastatic breast cancer. Cochrane Database Syst Rev 3:003366
4. McGrogan BT, Gilmartin B, Carney DN, McCann A (2008) Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta 1785:96-132
5. Winer EP, Berry DA, Woolf S, Duggan D, Kornblith A, Harris LN, Michaelson RA, Kirshner JA, Fleming GF, Perry MC, Graham ML, Sharp SA, Keresztes R, Henderson IC, Hudis C, Muss H, Norton L (2004) Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol 22:2061-2068 (Pubitemid 41095138)
6. Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, Ungaro P, Norton L, Winer E, Hudis C (2008) Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26:1642-1649
7. Wang Q, Yang W, Uytingco MS, Christakos S, Wieder R (2000) 1, 25 (OH) 2 vitamin D3 and all-trans retinoic acid sensitize breast cancer cells to chemotherapy-induced cell death. Cancer Res 60:2040-2048 (Pubitemid 30207668)
8. Sutton LM, Warmuth MA, Petros WP, Winer EP (1997) Pharmacokinetics and clinical impact of all-trans retinoic acid in metastatic breast cancer: a phase II trial. Cancer Chemother Pharmacol 40:335-341 (Pubitemid 27276138)
9. Kurie JM, Lee JS, Griffin T, Lippman SM, Drum P, Thomas MP, Weber C, Bader M, Massimini G, Hong WK (1996) Phase I trial of 9-cis retinoic acid in adults with solid tumors. Clin Cancer Res 2:287-293 (Pubitemid 26074616)
10. Esteva FJ, Glaspy J, Baidas S, Laufman L, Hutchins L, Dickler M, Tripathy D, Cohen R, DeMichele A, Yocum RC, Osborne CK, Hayes DF, Hortobagyi GN, Winer E, Demetri GD (2003) Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J Clin Oncol 21:999-1006 (Pubitemid 46594127)
11. Conley B, O'Shaughnessy J, Prindiville S, Lawrence J, Chow C, Jones E, Merino MJ, Kaiser-Kupfer MI, Caruso RC, Podgor M, Goldspiel B, Venzon D, Danforth D, Wu S, Noone M, Goldstein J, Cowan KH, Zujewski J (2000) Pilot trial of the safety, tolerability, and retinoid levels of N-(4-hydroxyphenyl) retinamide in combination with tamoxifen in patients at high risk for developing invasive breast cancer. J Clin Oncol 18:275-283 (Pubitemid 30056415)
12. Lawrence JA, Adamson PC, Caruso R, Chow C, Kleiner D, Murphy RF, Venzon DJ, Shovlin M, Noone M, Merino M, Cowan KH, Kaiser M, O'Shaughnessy J, Zujewski J (2001) Phase I clinical trial of alitretinoin and tamoxifen in breast cancer patients: toxicity, pharmacokinetic, and biomarker evaluations. J Clin Oncol 19:2754-2763 (Pubitemid 32441382)
13. Budd GT, Adamson PC, Gupta M, Homayoun P, Sandstrom SK, Murphy RF, McLain D, Tuason L, Peereboom D, Bukowski RM, Ganapathi R (1998) Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer. Clin Cancer Res 4:635-642 (Pubitemid 28193562)
14. Perez EA, Vogel CL, Irwin DH, Kirshner JJ, Patel R (2001) Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 19:4216-4223 (Pubitemid 33081639)
15. Verrill MW, Lee J, Cameron DA, Agrawal R, Coleman RE, McAdam K, Wardley A, Bowman A, Ferrigan L, Yellowlees A (2007) Anglo-Celtic IV: first results of a UK National Cancer Research Network randomized phase III pharmacogenetic trial of weekly compared to 3 weekly paclitaxel in patients with locally advanced or metastatic breast cancer (ABC). J Clin Onc 2007 ASCO Annual Meeting Proceedings 25:33S
16. Kawamata H, Tachibana M, Fujimori T, Imai Y (2006) Differentiation- inducing therapy for solid tumors. Curr Pharm Des 12:379-385
17. Shiah SG, Chuang SE, Kuo ML (2001) Involvement of Asp-Glu-Val-Asp- directed, caspase-mediated mitogen-activated protein kinase kinase 1 Cleavage, c-Jun. N-terminal kinase activation, and subsequent Bcl-2 phosphorylation for paclitaxel-induced apoptosis in HL-60 cells. Mol Pharmacol 59:254-262
18. Wang Q, Wieder R (2004) All-trans retinoic acid potentiates Taxotere-induced cell death mediated by jun N-terminal kinase in breast cancer cells. Oncogene 23:426-433 (Pubitemid 38174997)
19. Wang Q, Lee D, Sysounthone V, Chandraratna RAS, Christakos S, Korah R, Wieder R (2001) 1, 25-dihydroxyvitamin D3 and retinoic acid analogues induce differentiation in breast cancer cells with function-and cell-specific additive effects. Breast Cancer Res Treat 67:157-168 (Pubitemid 32744496)
20. Toma S, Raffo P, Nicolo G, Canavese G, Margallo E, Vecchio C, Dastoli G, Iacona I, Regazzi-Bonora M (2000) Biological activity of all-trans-retinoic acid with and without tamoxifen and alphainterferon 2a in breast cancer patients. Int J Oncol 17:991-1000